Opioid δ-receptor agonists show promise for treating IBS-like symptoms

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and reducing stress-induced hypermotility.

Researchers ‘stunned’ after HHMI abruptly cancels program to make science more inclusive

The Howard Hughes Medical Institute, the nation’s largest private funder of biomedical research, this week abruptly ended a $60 million program aimed at improving the

February 7, 2025

Risk Adjusted Net Present Value: What is the current valuation of GeoVax Labs’s Gedeptin

The revenue for Gedeptin is expected to reach an annual total of $15 mn by 2039 in the US based off GlobalData’s Expiry Model. The

July 31, 2023

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | Psychedelic Invest

TORONTO, July 02, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused

July 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.